PomDoctor (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, saw its stock price soar 7.20% in after-hours trading on Wednesday, continuing its strong performance following its Nasdaq debut earlier in the day. The surge comes on the heels of the company's successful initial public offering (IPO) and impressive intraday trading results.

The company priced its IPO at $4.00 per American Depositary Share (ADS), offering 5,000,004 ADSs and raising approximately $20 million in gross proceeds. During regular trading hours, PomDoctor's stock had already shown significant strength, rising 5% from its IPO price to close at $4.20. The additional after-hours gain suggests continued investor enthusiasm for the newly public company.

PomDoctor's strong market debut and subsequent after-hours rally indicate positive investor sentiment towards the company's business model and growth prospects. As a platform focusing on chronic disease management and pharmaceutical services in China, PomDoctor aims to enhance the efficiency and transparency of the healthcare value chain. The successful IPO and robust trading performance may provide the company with increased visibility and resources to pursue its mission of becoming the most trustworthy medical and healthcare services platform in China.